Simplicity Solutions LLC Acquires 375 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Simplicity Solutions LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 23.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,997 shares of the biopharmaceutical company’s stock after buying an additional 375 shares during the period. Simplicity Solutions LLC’s holdings in Alnylam Pharmaceuticals were worth $382,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ALNY. Norges Bank bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth $240,703,000. Wellington Management Group LLP boosted its holdings in shares of Alnylam Pharmaceuticals by 6.0% during the 3rd quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock valued at $1,139,074,000 after purchasing an additional 364,021 shares during the last quarter. Eaton Vance Management grew its position in shares of Alnylam Pharmaceuticals by 606.7% during the first quarter. Eaton Vance Management now owns 306,228 shares of the biopharmaceutical company’s stock valued at $50,005,000 after purchasing an additional 262,893 shares in the last quarter. Ameriprise Financial Inc. grew its position in shares of Alnylam Pharmaceuticals by 328.9% during the first quarter. Ameriprise Financial Inc. now owns 203,170 shares of the biopharmaceutical company’s stock valued at $40,699,000 after purchasing an additional 155,795 shares in the last quarter. Finally, Royal London Asset Management Ltd. increased its holdings in shares of Alnylam Pharmaceuticals by 86.7% in the third quarter. Royal London Asset Management Ltd. now owns 306,595 shares of the biopharmaceutical company’s stock worth $54,303,000 after purchasing an additional 142,357 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. raised their price target on Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a “neutral” rating in a report on Thursday, February 1st. Wolfe Research started coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They issued a “peer perform” rating on the stock. Cantor Fitzgerald reiterated a “neutral” rating and set a $165.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Royal Bank of Canada restated an “outperform” rating and issued a $235.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. Finally, Morgan Stanley lowered their price target on shares of Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, February 13th. Eight equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $216.12.

Alnylam Pharmaceuticals Trading Down 0.5 %

NASDAQ:ALNY opened at $144.41 on Friday. The company has a market cap of $18.19 billion, a price-to-earnings ratio of -40.56 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a twelve month low of $143.50 and a twelve month high of $218.88. The stock has a fifty day simple moving average of $151.56 and a 200-day simple moving average of $166.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.10. The company had revenue of $439.72 million for the quarter, compared to the consensus estimate of $439.38 million. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.68) EPS. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -4.54 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.